Inivata and Agendia Sign Agreement for Commercialization of RaDaR® MRD Liquid Biopsy Assay in Breast Cancer
April 28, 2021 07:00 ET
|
Inivata
Inivata and Agendia Sign Agreement for Commercialization of RaDaR® MRD Liquid Biopsy Assay in Breast Cancer Agendia granted co-exclusive distribution rights for RaDaR in North America and Europe ...
Inivata publishes positive clinical validation results and real-world utility for its InVisionFirst®-Lung liquid biopsy test
April 26, 2019 07:00 ET
|
Inivata
Inivata publishes positive clinical validation results and real-world utility for its InVisionFirst®-Lung liquid biopsy test InVisionFirst®-Lung demonstrated excellent concordance with tissue...
Inivata Receives Medicare Final Coverage Decision for InVisionFirstTM-Lung Liquid Biopsy Test in Advanced Non-Small Cell Lung Cancer
March 05, 2019 07:00 ET
|
Inivata
Inivata Receives Medicare Final Coverage Decision for InVisionFirstTM-Lung Liquid Biopsy Test in Advanced Non-Small Cell Lung Cancer Final Coverage Supports the Use of InVisionFirst-Lung for Aiding...
Inivata Achieves Major Milestone with Draft Medicare Local Coverage Determination (LCD) for InVisionFirst™-Lung Liquid Biopsy Test
September 13, 2018 13:07 ET
|
Inivata
Inivata Achieves Major Milestone with Draft Medicare Local Coverage Determination (LCD) for InVisionFirst™-Lung Liquid Biopsy Test Draft Coverage Supports the Use of InVisionFirst-Lung for Aiding...
Inivata Strengthens Senior Leadership Ahead of Next Stage of Company Growth
September 12, 2018 07:00 ET
|
Inivata
Inivata Strengthens Senior Leadership Ahead of Next Stage of Company Growth Research Triangle Park, NC and Cambridge, UK, September 12, 2018 -- Inivata, a leader in liquid biopsy, today announces...